BioLife Solutions Expands Evidence Library With Citations of Bioproduction Tools in Scientific and Clinical Research
BioLife Solutions’ refreshed Evidence Library offers a comprehensive collection of published data on the use of biopreservation tools in cell and gene therapy. With enhanced navigation and search capabilities, users can easily explore scientific evidence supporting the adoption of products like CryoStor®, HypoThermosol®, and more.
Journal Articles Citing CryoStor CS10® Recently Added to BioLife Solutions’ Evidence Library
Multiple Uses for CryoStor in Cell Manufacturing Journal articles recently added to BioLife Solutions’ Evidence Library illustrate several stages during the cell manufacturing process for which CryoStor CS10® cryopreservation solution is applicable. The three articles that follow include several different cell types cryopreserved in CryoStor CS10. An expanded list of cell types biopreserved in BioLife […]
Cellular Therapies for COVID-19 Highlighted During ISCT Paris 2020 (VIRTUAL)
The global impact of COVID-19 on our lives has been profound at virtually every level. Personally, professionally, politically, and economically, the pandemic impacts our lives, our relationships, and how we conduct business. We begin and end the day with the latest news on SARS-CoV-2, and up-to-the-minute COVID-19 data. In between, we must surmount any number […]
Journal Articles Citing Cryopreservation Component Recently Added to BioLife Solutions’ Evidence Library
Cryopreservation adds flexibility to timelines when working with cells. In the case of cellular therapies, that can mean initial flexibility to schedule patient cell collection, transport cells to the manufacturing facility and initiate manufacturing. Cryopreservation of the final cell therapy product adds flexibility to be able to schedule the return of cells to the patient […]
Joining Forces!
BioLife Solutions issued a press release August 8, 2019, announcing the execution of a share exchange agreement to purchase the remaining 56% of shares of SAVSU Technologies that BioLife did not previously own. BioLife’s relationship with Savsu spans six years, during the development and growth of the evo® Cold Chain 2.0™ system, encompassing evo® hardware […]